HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem (Q37958563)

25 August 2017

title

HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem (English)

1 reference

25 August 2017

0 references

1 reference

1 reference

Wayne C Koff

1

1 reference

25 August 2017

language of work or name

English

0 references

publication date

17 November 2011

1 reference

25 August 2017

number of pages

6

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

25 August 2017

volume

30

1 reference

25 August 2017

issue

29

1 reference

25 August 2017

page(s)

4310-4315

1 reference

Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Detection, Isolation, and Continuous Production of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and Pre-AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Enhanced control of pathogenic Simian immunodeficiency virus SIVmac239 replication in macaques immunized with an interleukin-12 plasmid and a DNA prime-viral vector boost vaccine regimen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

HIV-1 vaccine development after STEP.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Rational modifications of HIV-1 envelope glycoproteins for immunogen design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Exploiting the defensive sugars of HIV-1 for drug and vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Structural definition of a conserved neutralization epitope on HIV-1 gp120

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Role of HIV membrane in neutralization by two broadly neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Antibody 2G12 Recognizes Di-Mannose Equivalently in Domain- and Nondomain-Exchanged Forms but Only Binds the HIV-1 Glycan Shield if Domain Exchanged

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Broad neutralization coverage of HIV by multiple highly potent antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Inhibition of HIV-1 infectivity and epithelial cell transfer by human monoclonal IgG and IgA antibodies carrying the b12 V region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

HIV vaccine design and the neutralizing antibody problem

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Antibodies, viruses and vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Antibody binding is a dominant determinant of the efficiency of human immunodeficiency virus type 1 neutralization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Biochemical and immunogenic characterization of soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by semliki forest virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Purification, Characterization, and Immunogenicity of a Soluble Trimeric Envelope Protein Containing a Partial Deletion of the V2 Loop Derived from SF162, an R5-Tropic Human Immunodeficiency Virus Type 1 Isolate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.014

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2011.11.014

1 reference

25 August 2017

1 reference